BCL2 and breast carcinoma: Kaban et al. used BCL-2 siRNA-loaded exosomes derived from genetically modified NK cells to treat ER+ breast cancer, resulting in the increased intrinsic apoptosis pathway in cancer cells, while non-malignant cells were not affected [97].